Enter your email address to receive updates
Search By Trade Name
Trade name | Generic name | Classification
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z 
Generic Name
Octreotide
Trade Name
Sandostatin LAR Depot
Risk Category
B
  • Controlled studies done on animals in reproduction do not indicate risk to the fetus.
  • No adequate and well-controlled studies done on pregnant women.
FDA Pregnancy Risk Categories

Place (not click) your mouse cursor over the bold words in the text below to receive description

Indication
Indication
  • Analogue of somatostatin for treatment of:
  • Acromegaly.
  • Carcinoid tumors.
  • Variceal bleeding.
  • To reduce insulin requirement in diabetics.
  • To reduce output of gastrointestinal and pancreatic fistulas.
  • Fetal Risk
    Fetal Risk
  • Not teratogenic or toxic in animals.
  • Crosses human placenta.
  • Limited human data but no congenital defects have been reported in 1st trimester exposure.
  • Breast Feeding
    Breast Feeding
  • It is not known whether Octreotide is excreted into human milk.
  • Because many drugs are excreted in human milk, caution should be exercised when Octreotide is administered to a nursing woman.
  • Other Trade Names
     
    The information on this Web site is not intended as a substitute for the advice and care of your doctor or other health-care provider. Always consult your doctor if you have any questions about exposures during pregnancy and lactation, and before you take any medications. Please read the Terms and Conditions before using this website.
      Tell A Friend

        You
    Name
    Email
        Your Friend
    Name
    Email
        Comments
     6   +   7    =  
      Calculate Birth Date
    Enter the first day of the last menstruation
    Month Day Year
    Result
    Month Day Year